The New Frontier of Oncology: Inside Reed Jobs’ Yosemite Venture

Three years after its inception, Yosemite, the oncology-focused venture firm founded by Reed Jobs, has evolved from a boutique experiment into a formidable architect of modern medicine. Jobs, often recognized by his surname but defined by his distinct approach to biotech, has spent the last 36 months building a portfolio that challenges the traditional boundaries of drug discovery. By blending the patience of philanthropy with the high-stakes discipline of venture capital, Yosemite is positioning itself at the intersection of artificial intelligence and the "patent cliff" currently reshaping the pharmaceutical industry.

The Genesis and Evolution of Yosemite

When Yosemite launched in 2023, the biotech sector was navigating a brutal post-pandemic correction. Interest rates were climbing, and investor sentiment was cooling. Yet, for Jobs, the environment was not a deterrent but a catalyst. "When I launched Yosemite in 2023, the XBI [biotech index] was still down massively from its 2021 highs and pharma hadn’t gotten acquisitive yet," Jobs recalls.

Today, the firm manages a growing portfolio of nearly 25 companies, supported by a team of 17 experts. The firm operates with a unique hybrid model: it utilizes no-strings-attached philanthropic grants to de-risk embryonic academic research, transitioning those successes into venture-backed companies. Approximately one-third of the firm’s $350 million second fund is dedicated to "company building"—spinning out novel therapeutic approaches directly from institutions like Yale, Stanford, and UC Berkeley.

Chronology: From Lab Bench to Clinical Reality

The trajectory of Yosemite’s portfolio reflects a rapid maturation process. In the early days, the firm focused on foundational science; today, several of those bets are entering clinical trials.

• 2023: Yosemite debuts at TechCrunch Disrupt, articulating a thesis that the next generation of cancer cures would not be found in existing pharma pipelines but built from scratch through academic collaboration.
• 2024: The firm deepens its commitment to "induced proximity"—a therapeutic strategy where drugs are designed to physically maneuver disease-causing proteins toward the cell’s internal disposal system. Portfolio company Quarry Therapeutics emerges as a leader in this space.
• 2025: The "patent cliff" begins to exert massive pressure on global pharmaceutical giants. As blockbuster drugs lose exclusivity, companies like Eli Lilly initiate aggressive acquisition strategies, such as the $7 billion purchase of Kelonia, signaling a new era of exit liquidity for early-stage innovators.
• 2026: AI moves from a buzzword to a primary engine of discovery within Yosemite’s labs. Tools that once took years to map protein surfaces are now identifying "cryptic pockets" on previously "undruggable" targets like KRAS and p53, revolutionizing how oncologists approach the disease.

The AI Revolution in Drug Discovery and Clinical Trials

Perhaps the most significant shift in Yosemite’s strategy has been the integration of artificial intelligence. While some critics argue that AI in biotech is overhyped, Jobs maintains a pragmatic view: AI is an engine for acceleration, not a magic wand.

"What AI is doing right now is accelerating a lot of grunt work—not necessarily doing it better, but doing it incredibly fast, with reproducible outcomes," Jobs explains.

Beyond discovery, the firm is banking on AI to dismantle the primary bottleneck of modern medicine: clinical trials. A Phase 3 cancer trial currently costs roughly $260 million, with a high failure rate often attributed to poor patient recruitment. Yosemite is exploring the use of "synthetic control arms," where AI models simulate the control group using historical patient data. This approach could potentially halve the number of human participants required for trials, drastically reducing both time and cost.

Strategic Focus: Targeting the "Undruggable"

Yosemite’s scientific ambition is best illustrated by its assault on the "Achilles’ heels" of cancer. Among the most prominent targets is p53, a tumor suppressor gene often disabled in human cancers.

"p53 is the most frequently suppressed gene across human cancers; almost every cancer has to knock it out to exist in the first place," says Jobs. Yosemite is currently backing three different companies utilizing distinct strategies to either turn p53 back on or attack its mutated forms.

Furthermore, the firm’s work with Tune Therapeutics on epigenetic editing—the process of adding or removing chemical tags to silence viral or cancerous genes—represents a shift from reactive medicine to proactive, targeted biological engineering. By mimicking the natural silencing of viruses observed in a small percentage of human patients, Tune is targeting hepatitis B, a major precursor to liver cancer.

The Role of Public Policy and Federal Funding

Jobs remains a vocal advocate for the National Institutes of Health (NIH), viewing federal funding as the bedrock upon which the entire venture-backed biotech ecosystem is built. Last year, when proposals surfaced to cut the NIH budget by up to 40%, the scientific community—and investors like Jobs—rallied to protect the agency.

"NIH funding has more than 90% approval," Jobs notes. "Personally, I think we should go on offense—I’d increase it to something like $100 billion." He argues that because NIH funding has remained largely stagnant for a decade, it has effectively shrunk in real terms due to inflation, threatening the very pipeline of basic research that firms like Yosemite rely upon to create new companies.

Implications for the Future of Oncology

As Yosemite matures, its impact extends beyond its own portfolio. The firm’s willingness to operate as an "open door" for both Nobel laureates and first-time grant recipients has democratized access to venture capital. By stripping away pedigree and focusing solely on the scientific merit of a proposal, Jobs is attempting to shift the culture of biotech toward a more egalitarian, results-oriented framework.

Looking ahead, the emergence of GLP-1 drugs as a "pan-disease" protective factor—offering potential benefits against cancer and neurodegeneration—has created new optimism. This has allowed Yosemite and its peers to revisit disease categories that had previously been considered "cold" or uninvestable.

"I didn’t expect Yosemite to be moving this fast," Jobs admits. "This time is more important than I realized, which is both scarier and more empowering."

Conclusion: The Business of Curing

While Jobs is quick to downplay the "longevity industry" as a one-size-fits-all business—arguing instead for a personalized, cell-specific understanding of aging—his focus remains firmly on the tangible. He acknowledges that while storytelling is a critical component for any CEO, the division of labor between the academic founder (the scientist) and the operational CEO (the manager) is essential for success.

For now, the strategy at Yosemite is clear: follow the science, leverage the data, and remain agile enough to move when the pharmaceutical landscape shifts. Whether it is through ultrasound-based histotripsy via Histosonics or the delicate manipulation of gene expression, Reed Jobs is betting that the most effective way to solve cancer is to stop waiting for the cure to appear and start building it, one molecule at a time.